ICG Dye Imaging for Cancer Surgery
Trial Summary
What is the purpose of this trial?
This trial uses a special dye called ICG to help surgeons see and remove bone or soft tissue tumors more effectively. The dye lights up the tumor under a special camera, making it easier to ensure all of it is removed. This approach aims to improve surgical outcomes for patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the drug Indocyanine Green (ICG) for cancer surgery?
Research shows that Indocyanine Green (ICG) is effective in helping surgeons see and remove tumors more safely by highlighting important structures and improving surgical outcomes. It is used in various surgeries, including colorectal and breast cancer, to identify lymph nodes and assess blood flow, making surgeries more precise and reducing complications.12345
Is indocyanine green (ICG) dye safe for use in humans?
How is the drug Indocyanine green (ICG) unique for cancer surgery?
Indocyanine green (ICG) is unique for cancer surgery because it is a dye that helps surgeons see tumors and important structures during surgery using fluorescence (a special light that makes the dye glow). This makes it easier to locate tumors and ensure proper blood flow to tissues, which is different from traditional methods that don't use this glowing effect.1011121314
Research Team
Santiago A Lozano-Calderon, MD, PhD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for adults over 18 with benign or malignant bone or soft tissue masses who are undergoing surgery at Massachusetts General Hospital's Orthopaedic Surgery Department. It excludes those in renal failure not cleared for ICG, pregnant or nursing individuals, and patients with known anaphylaxis to IV contrast or iodine.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preoperative
ICG is administered via IV injection approximately 4 hours before surgery
Surgery
ICG fluorescence imaging is performed during and immediately after tumor resection to ensure negative margins
Follow-up
Participants are monitored for local recurrence and metastatic disease
Treatment Details
Interventions
- Indocyanine green (Dye)
Indocyanine green is already approved in Canada, Japan for the following indications:
- Diagnostic imaging of the lymphatic system
- Ophthalmic angiography
- Cardiovascular imaging
- Diagnostic imaging of the lymphatic system
- Ophthalmic angiography
- Cardiovascular imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Dr. William Curry
Massachusetts General Hospital
Chief Medical Officer
MD from Harvard Medical School
Dr. Anne Klibanski
Massachusetts General Hospital
Chief Executive Officer since 2019
MD from Harvard Medical School